Ranizurel 0.5mg Injection

Reviews How to Use Benefits Uses Side Effects

Product Info

Prescription required	Yes
Marketer	Reliance Life Sciences
Active Ingredient	Ranibizumab (0.5mg)
Storage	Store in a refrigerator (2 - 8°C). Do not freeze.
Chemical Class	Monoclonal antibody (mAb)
Habit Forming	No
Therapeutic Class	OPHTHAL
Action Class	Vascular endothelial growth factor (VEGF) inhibitor for AMD
User Rating	4.6
User Reviews	677

FAQ

What precautions should I take after taking Ranizurel 0.5mg?

After taking Ranizurel 0.5mg:
a. You should not wash your face and hair or shower for 48 hours
b. Avoid rubbing your eyes
c. Avoid swimming for a week. Consult your doctor in case of any doubts
d. Do not wear contact lenses immediately after injection. You may wear spectacles instead
e. Give complete rest to your eyes and do not strain by looking at television, mobile phones, or computer screens for 1-2 days.

What is the duration of treatment for Ranizurel 0.5mg?

Ranizurel 0.5mg is recommended to be initially administered by intravitreal injection (into the eye) once a month (approximately 28 days) for up to 3 months.

Who should not take Ranizurel 0.5mg?

Ranizurel 0.5mg should not be taken by individuals who are allergic to the medication or have an active eye infection.

What if you forget to take Ranizurel Injection?

If you miss a dose of Ranizurel 0.5mg, please consult your doctor.\n

Ranizurel 0.5mg Injection Reviews

Ranizurel 0.5mg is used for the treatment of eye diseases which are caused by diabetes, macular degeneration, and macular swelling. It reduces the abnormal growth and leakage of blood vessels in the eye that can cause vision loss.

Ranizurel 0.5mg is administered directly into the eyeball by an eye specialist. You should not self administer this medicine at home. The common side effects include conjunctival hemorrhage, eye pain, eye floaters, increased intraocular pressure, and eye inflammation.

However, if you experience these side effects for a longer duration or any other symptoms which you think may be due to this medicine, please inform your doctor. It is not advised to drive after administration of this injection as it may cause blurring of vision.

How Ranizurel 0.5mg Injection Works

Ranizurel 0.5mg is an anti-angiogenic medication. It works by blocking a protein called vascular endothelial growth factor (VEGF). This stops the growth and leakage of abnormal blood vessels in the eye(s) that may cause vision loss.

How to Use Ranizurel 0.5mg Injection

Your doctor or nurse will give you this medicine. Kindly do not self administer.

Benefits of Ranizurel 0.5mg Injection

In Macular edema due to retinal vein occlusion: Retinal vein occlusion is a blockage of the small veins that carry blood away from the retina, which is that part of the eye that is responsible for vision. So, retinal vein occlusion often causes permanent damage to the retina and loss of vision. It can also lead to other eye problems. Sometimes there is a complete loss of vision almost immediately. Ranizurel 0.5mg helps treat swelling of the macula that can cause vision disturbances.
In Wet age-related macular degeneration: Macula is the part of the retina responsible for central vision. Wet age-related macular degeneration is an eye disorder that causes blurred vision or a blind spot in your visual field due to abnormal blood vessels that leak fluid or blood into the macula. This leads to vision problems. Ranizurel 0.5mg helps prevent leakage of such abnormal blood vessels and therefore prevents vision loss. It is given as an injection by a doctor or nurse and should not be self-administered.
In Diabetic eye disease: Diabetic eye disease is a group of eye problems seen in people with diabetes. It can lead to vision loss, weak eyesight or even blindness. Ranizurel 0.5mg helps prevent this damage caused by diabetes and stops the worsening of vision. Consult your doctor if you have any doubts.

Uses of Ranizurel 0.5mg Injection

Diabetic eye disease
Macular edema due to retinal vein occlusion
Wet age-related macular degeneration

Ranizurel 0.5mg Injection Side Effects

Safety Tips

Pregnancy ^{CONSULT YOUR DOCTOR}

Ranizurel 0.5mg may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Kidney ^{SAFE IF PRESCRIBED}

Ranizurel 0.5mg is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Ranizurel 0.5mg may not be needed in these patients. Please consult your doctor.

Alcohol ^{CONSULT YOUR DOCTOR}

It is not known whether it is safe to consume alcohol with Ranizurel 0.5mg. Please consult your doctor.

Liver ^{SAFE IF PRESCRIBED}

Ranizurel 0.5mg is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Ranizurel 0.5mg may not be needed in these patients. Please consult your doctor.

Driving ^UNSAFE

Ranizurel 0.5mg may cause blurring of your vision for a short time just after its use. Do not drive until your vision is clear.

Breast feeding ^{SAFE IF PRESCRIBED}

Ranizurel 0.5mg is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.

Quick Tips

Use eye drops if they are prescribed to you by your doctor.
Ask your doctor if you should avoid any particular activities.
Inform your doctor if you experience increased eye pain and redness, blurred or decreased vision, or increased sensitivity to light.
Try to rest your eyes as much as possible (for at least a few hours).
Wear sunglasses if your eyes feel sensitive to light
It may cause temporary visual disturbances. Don't drive or do anything that requires mental focus until you know how Ranizurel 0.5mg affects you.

References

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1196-97.
Ranibizumab. South San Francisco, California: Genentech, Inc.; 2006.
Ranibizumab. Camberley, Surrey: Novartis Pharmaceuticals UK Ltd.; 2007 [revised 26 Jul. 2018].
Drugs.com. Ranibizumab.
Henderer JD, Rapuano CJ. Ocular Pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. New York, New York: McGraw-Hill Medical; 2011. p. 1794.
Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 977.